Published in Biotech Law Weekly, October 20th, 2006
The recent filing strengthens Auriga's business model to acquire and develop proprietary brands in the prescription drug marketplace, and then to maximize potential revenues through aggressive and broad intellectual property protection and innovative sales and marketing strategies.
The proprietary technology will be used to expand such Auriga brands as the Extendryl line, which currently comprises seven different prescription drug products. Extendryl is one of the company's...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.